Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23329845 | 0.91 | CACNA1H (0.32) | CACNA1HPDE2APDE10ATRPC6ALOX5AP | |
| SCHEMBL23329545 | 0.90 | PDE2A (0.32) | PDE2APDE10A | |
| SCHEMBL23330035 | 0.81 | PDE2A (0.33) | PDE2APDE10A | |
| SCHEMBL23330048 | 0.80 | PDE10A (0.33) | PDE2APDE10A | |
| SCHEMBL23330254 | 0.78 | ACACB (0.32) | PDE2APDE10AALOX5AP | |
| SCHEMBL23329926 | 0.77 | BRD4 (0.32) | PDE2A | |
| SCHEMBL21354655 | 0.76 | CACNA1H (0.33) | CACNA1HMTNR1AMTNR1B | |
| SCHEMBL23330032 | 0.75 | ALDH1A1 (0.30) | ALOX5AP | |
| SCHEMBL23329869 | 0.74 | RORC (0.32) | — | |
| SCHEMBL23329953 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | CACNA1H 70/4885PDE2A 1992/4885PDE10A 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.